ACS Medicinal Chemistry Letters最新文献

筛选
英文 中文
Announcing the 2024 ACS Division of Medicinal Chemistry Award Recipients: Celebrating Excellence in Medicinal Chemistry 宣布2024年ACS药物化学部门获奖者:庆祝药物化学卓越
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-06-12 DOI: 10.1021/acsmedchemlett.5c0025710.1021/acsmedchemlett.5c00257
Lori Ferrins,  and , Paul C. Trippier, 
{"title":"Announcing the 2024 ACS Division of Medicinal Chemistry Award Recipients: Celebrating Excellence in Medicinal Chemistry","authors":"Lori Ferrins,  and , Paul C. Trippier, ","doi":"10.1021/acsmedchemlett.5c0025710.1021/acsmedchemlett.5c00257","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00257https://doi.org/10.1021/acsmedchemlett.5c00257","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"902–905 902–905"},"PeriodicalIF":3.5,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In this Issue Volume 16, Issue 6 第16卷,第6期
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-06-12 DOI: 10.1021/acsmedchemlett.5c0029310.1021/acsmedchemlett.5c00293
Simone V. Bigi-Botterill, 
{"title":"In this Issue Volume 16, Issue 6","authors":"Simone V. Bigi-Botterill, ","doi":"10.1021/acsmedchemlett.5c0029310.1021/acsmedchemlett.5c00293","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00293https://doi.org/10.1021/acsmedchemlett.5c00293","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"906 906"},"PeriodicalIF":3.5,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Substituted Pyrazoles as 5-HT1A Agonists for Treating Neuropsychiatric Diseases 新型取代吡唑作为5-HT1A激动剂治疗神经精神疾病
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 DOI: 10.1021/acsmedchemlett.5c0030610.1021/acsmedchemlett.5c00306
Ram W. Sabnis*, 
{"title":"Novel Substituted Pyrazoles as 5-HT1A Agonists for Treating Neuropsychiatric Diseases","authors":"Ram W. Sabnis*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0030610.1021/acsmedchemlett.5c00306","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00306https://doi.org/10.1021/acsmedchemlett.5c00306","url":null,"abstract":"<p >Provided herein are novel substituted pyrazoles as 5-HT1A agonists, pharmaceutical compositions, use of such compounds in treating neuropsychiatric diseases, and processes for preparing such compounds.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"978–979 978–979"},"PeriodicalIF":3.5,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suzuki–Miyaura Coupling of Pinacolboronic Esters Catalyzed by a Well-Defined Palladium N-Heterocyclic Carbene (NHC) Catalyst 一种定义良好的n -杂环钯(NHC)催化剂催化的双硼酸酯的Suzuki-Miyaura偶联
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 DOI: 10.1021/acsmedchemlett.5c0020610.1021/acsmedchemlett.5c00206
Aleksei A. Logvinov, Geert Rombouts, Matthieu Jouffroy* and Steven P. Nolan*, 
{"title":"Suzuki–Miyaura Coupling of Pinacolboronic Esters Catalyzed by a Well-Defined Palladium N-Heterocyclic Carbene (NHC) Catalyst","authors":"Aleksei A. Logvinov,&nbsp;Geert Rombouts,&nbsp;Matthieu Jouffroy* and Steven P. Nolan*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0020610.1021/acsmedchemlett.5c00206","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00206https://doi.org/10.1021/acsmedchemlett.5c00206","url":null,"abstract":"<p >We report a versatile synthetic method for coupling heteroaryl chlorides and bromides with (hetero)aryl pinacolboronic esters of pharmaceutical interest at low catalyst loading of a well-defined palladium-NHC catalyst providing products in good to high isolated yield and purity in short reaction time. The method displays remarkably broad applicability with both 5- and 6-membered heterocycles.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"1170–1174 1170–1174"},"PeriodicalIF":3.5,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pyrroloquinolone-Based Compounds as a Novel Antimycobacterial Chemotype 吡咯喹诺酮类化合物作为一种新型抗细菌化学型
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 DOI: 10.1021/acsmedchemlett.5c0018310.1021/acsmedchemlett.5c00183
Marta Clariano, Diogo Nunes, Daniela Canudo, Daniela Maçãs, Bruno J. L. Castro, Audrey Jordaan, Pedro Gomes, Anna Contini, João Perdigão, Isabel Portugal, Margarida Madureira, Digby F. Warner, Marco Pieroni, Maria de Jesus Perry* and Francisca Lopes*, 
{"title":"Pyrroloquinolone-Based Compounds as a Novel Antimycobacterial Chemotype","authors":"Marta Clariano,&nbsp;Diogo Nunes,&nbsp;Daniela Canudo,&nbsp;Daniela Maçãs,&nbsp;Bruno J. L. Castro,&nbsp;Audrey Jordaan,&nbsp;Pedro Gomes,&nbsp;Anna Contini,&nbsp;João Perdigão,&nbsp;Isabel Portugal,&nbsp;Margarida Madureira,&nbsp;Digby F. Warner,&nbsp;Marco Pieroni,&nbsp;Maria de Jesus Perry* and Francisca Lopes*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0018310.1021/acsmedchemlett.5c00183","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00183https://doi.org/10.1021/acsmedchemlett.5c00183","url":null,"abstract":"<p >Tuberculosis, caused by <i>Mycobacterium tuberculosis</i> (Mtb), remains the world’s most lethal infectious disease, posing an uncontained health challenge. The major hurdles are the long treatments and low patient compliance that leads to the appearance of resistance, as well as the lack of drugs that effectively tackle the latent infections. Herein we report the development of compounds with the ability to target the electron transport chain of Mtb by inhibiting cytochrome <i>bcc</i> (cyt-<i>bcc</i>) (<b>7a</b>–<b>i</b>) and additionally being capable of inhibiting cytochrome <i>bd</i> (cyt-<i>bd</i>) (<b>7j</b> and <b>7k</b>). We present the synthesis, determination of physicochemical properties, evaluation of the antibacterial activity, and cytotoxicity assessment of pyrroloquinolone-based compounds. The antibacterial evaluation of <b>7a</b>–<b>k</b> showed selectivity toward mycobacteria, and the results identify cyt-<i>bcc</i> as their target. Compounds <b>7j</b> and <b>7k</b> presented promising results against Mtb and good physicochemical properties. Cytotoxicity assays revealed a good safety profile regarding the toxicity for human cell lines.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"1139–1146 1139–1146"},"PeriodicalIF":3.5,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Multiparameter Index Is a Strong Predictor of Oral Bioavailability for Heterobifunctional Degraders 新的多参数指标是异双功能降解剂口服生物利用度的有力预测指标
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 DOI: 10.1021/acsmedchemlett.5c0015610.1021/acsmedchemlett.5c00156
Javier L. Baylon*, Matthew J. Chalkley, Tony Siu, Wilson Shou, Yongnian Sun, Xianmei Cai, Anthony Paiva, Shivani Patel, Tatyana Zvyaga and Dahlia R. Weiss, 
{"title":"New Multiparameter Index Is a Strong Predictor of Oral Bioavailability for Heterobifunctional Degraders","authors":"Javier L. Baylon*,&nbsp;Matthew J. Chalkley,&nbsp;Tony Siu,&nbsp;Wilson Shou,&nbsp;Yongnian Sun,&nbsp;Xianmei Cai,&nbsp;Anthony Paiva,&nbsp;Shivani Patel,&nbsp;Tatyana Zvyaga and Dahlia R. Weiss,&nbsp;","doi":"10.1021/acsmedchemlett.5c0015610.1021/acsmedchemlett.5c00156","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00156https://doi.org/10.1021/acsmedchemlett.5c00156","url":null,"abstract":"<p >Ligand-directed degraders (LDDs) are heterobifunctional molecules that degrade proteins by engaging the ubiquitin-protein-ligase (E3) system. LDDs (also known as proteolysis-targeting chimeras) consist of a target-engaging moiety, an E3 ligase-binding moiety, and a bridging linker. Due to their size and physicochemical complexity, these molecules do not adhere to well-established rules of lead optimization. Achieving oral bioavailability remains a key challenge in the optimization of LDDs as therapeutic agents. In this study, we build on the previously established Balanced Permeability Index (BPI) (a metric that integrates size, polarity, and lipophilicity) by incorporating an additional descriptor to account for molecular shape. Our new combined metric, termed Bifunctional Bioavailability Index (BBI), can differentiate oral bioavailability of LDDs in our data set more effectively than polarity, lipophilicity, or size separately. Notably, BBI is also more effective than <i>in vitro</i> cell permeability assays in predicting orally bioavailable LDDs. These results support the use of BBI as a computational tool for designing and optimizing bioavailable bifunctional degraders.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"1108–1113 1108–1113"},"PeriodicalIF":3.5,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases 新型双环杂环作为MRGPRX2拮抗剂治疗炎性疾病
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-06-02 DOI: 10.1021/acsmedchemlett.5c0030510.1021/acsmedchemlett.5c00305
Ram W. Sabnis*, 
{"title":"Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases","authors":"Ram W. Sabnis*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0030510.1021/acsmedchemlett.5c00305","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00305https://doi.org/10.1021/acsmedchemlett.5c00305","url":null,"abstract":"<p >Provided herein are novel bicyclic heterocycles as MRGPRX2 antagonists, pharmaceutical compositions, use of such compounds in treating inflammatory diseases, and processes for preparing such compounds.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"980–981 980–981"},"PeriodicalIF":3.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144260942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Triazine Macrocycle Libraries: Synthesis, logD Prediction, and a Surprisingly Hydrophobic, Membrane-Permeable Diamine 三嗪大环文库:合成,logD预测,和一个令人惊讶的疏水,膜透性二胺
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-06-02 DOI: 10.1021/acsmedchemlett.5c0007810.1021/acsmedchemlett.5c00078
Gretel A. Stokes, Casey J. Patterson-Gardner, Alexander M. Engstrom, Alexander J. Menke, K. Harsha Vardhan Reddy, R. Scott Lokey and Eric E. Simanek*, 
{"title":"Triazine Macrocycle Libraries: Synthesis, logD Prediction, and a Surprisingly Hydrophobic, Membrane-Permeable Diamine","authors":"Gretel A. Stokes,&nbsp;Casey J. Patterson-Gardner,&nbsp;Alexander M. Engstrom,&nbsp;Alexander J. Menke,&nbsp;K. Harsha Vardhan Reddy,&nbsp;R. Scott Lokey and Eric E. Simanek*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0007810.1021/acsmedchemlett.5c00078","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00078https://doi.org/10.1021/acsmedchemlett.5c00078","url":null,"abstract":"<p >A library of triazine macrocycles was obtained to evaluate strategies for predicting lipophilicity using additive algorithms. Two synthetic routes were examined. While both were successful, one proved amenable to solution-phase library synthesis. The octanol–water partition coefficients (logP) were measured using reverse-phase HPLC at pH 10. When experimental and computed values (AlogP) are compared, a linear correlation is observed. That is, while additive algorithms underestimate hydrophobicity by a factor of 100, a simple correction yields accurate predictions. Two macrocycles showed anomalous hydrophobicities at high pH that were borne out in membrane transit (PAMPA) studies. Homodimers containing two primary amines were more hydrophobic than the corresponding heterodimers containing a single amine and a hydrophobic group. Structural analysis and computation provide a rationale for this behavior: the amines engage in an intramolecular hydrogen bond.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"1017–1023 1017–1023"},"PeriodicalIF":3.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144260870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Miniaturized Chemical High Throughput Experimentation Plate to Enable Late-Stage Oxidation Screening and Scale-up 一个小型化的化学高通量实验板,使后期氧化筛选和放大
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-06-02 DOI: 10.1021/acsmedchemlett.5c0017510.1021/acsmedchemlett.5c00175
Javier Izquierdo-Ferrer*, Mary E. Bellizzi, Noah Tu, Andrew Bogdan and Ying Wang, 
{"title":"A Miniaturized Chemical High Throughput Experimentation Plate to Enable Late-Stage Oxidation Screening and Scale-up","authors":"Javier Izquierdo-Ferrer*,&nbsp;Mary E. Bellizzi,&nbsp;Noah Tu,&nbsp;Andrew Bogdan and Ying Wang,&nbsp;","doi":"10.1021/acsmedchemlett.5c0017510.1021/acsmedchemlett.5c00175","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00175https://doi.org/10.1021/acsmedchemlett.5c00175","url":null,"abstract":"<p >Chemical methods for Late-Stage Oxidation (LSO) of advanced and complex molecules remain a highly relevant topic, with new and improved methods being reported annually. Despite the growing number of methodologies, the scope and limitations of these methods in bioactive molecules is largely unknown. We have designed a High-Throughput Experimentation (HTE) plate based on validated LSO methods, capable of screening compounds using only a few milligrams, to enhance our Late-Stage Functionalization (LSF) platform. Various projects at AbbVie have benefited from this plate, generating essential data for programs and creating new analogs for comprehensive Structure–Activity Relationship (SAR) analysis. We demonstrated the transformative capabilities of this approach by screening nine well-known drugs and analyzed the oxidized derivatives. This report highlights how this overlooked transformation can be an effective synthetic tool for medicinal chemistry.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"916–924 916–924"},"PeriodicalIF":3.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel 2,6,9-Trisubstituted Purines as CDK2 Inhibitors for Treating Cancers 新型2,6,9-三取代嘌呤作为CDK2抑制剂治疗癌症
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-05-30 DOI: 10.1021/acsmedchemlett.5c0028210.1021/acsmedchemlett.5c00282
Jian Rong,  and , Steven H. Liang*, 
{"title":"Novel 2,6,9-Trisubstituted Purines as CDK2 Inhibitors for Treating Cancers","authors":"Jian Rong,&nbsp; and ,&nbsp;Steven H. Liang*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0028210.1021/acsmedchemlett.5c00282","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00282https://doi.org/10.1021/acsmedchemlett.5c00282","url":null,"abstract":"<p >This highlight describes novel 2,6,9-trisubstituted purines as cyclin-dependent kinase 2 (CDK2) inhibitors. It details the novel 2,6,9-trisubstituted purine compounds, the pharmaceutical composition, use, and treatment for CDK2-related diseases, such as cancers.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"970–971 970–971"},"PeriodicalIF":3.5,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信